Can I Take Green Tea Extract (EGCG) with Praluent (Alirocumab)?

How Praluent (Alirocumab) Is Processed in the Body

Alirocumab does not rely on the liver's drug-metabolizing enzyme network in the way that statins do. As a fully human IgG1 monoclonal antibody, it is broken down through two parallel routes: target-mediated clearance (binding to PCSK9 and then being internalized and degraded) and nonspecific IgG catabolism via the reticuloendothelial system [1]. Neither pathway involves CYP3A4, CYP2C9, CYP1A2, or any other Phase I enzyme that botanical compounds commonly inhibit or induce.

Why CYP450 Irrelevance Matters for Supplement Interactions

Most clinically meaningful drug-supplement interactions occur because the supplement alters the rate at which a CYP450 enzyme clears the drug, producing higher or lower plasma drug concentrations than intended. St. John's Wort and CYP3A4 inducers are the textbook example. Because alirocumab bypasses this entire system, EGCG cannot reduce or raise its plasma exposure through enzyme modulation.

The FDA-approved prescribing information for alirocumab (Praluent) confirms: "Alirocumab is not metabolized by cytochrome P450 enzymes; therefore, interactions with drugs that are inducers or inhibitors of CYP enzymes are not expected" [2].

Pharmacodynamic Overlap

Alirocumab lowers LDL-C by blocking PCSK9-mediated degradation of hepatic LDL receptors, increasing the liver's capacity to clear circulating LDL particles. In the ODYSSEY LONG TERM trial (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by 61% at 24 weeks versus placebo [3]. EGCG does not meaningfully target the LDL receptor or PCSK9 pathway at supplemental doses, so there is no pharmacodynamic antagonism or additive effect of clinical relevance.

What the Evidence Says About EGCG and Cholesterol

Green tea catechins have been studied as lipid-lowering agents, and the data show modest, real effects. A 2011 Cochrane-style meta-analysis of 20 randomized controlled trials found that green tea consumption was associated with a mean LDL-C reduction of approximately 2.19 mg/dL (0.057 mmol/L) compared to control [4]. Statistically significant, clinically small.

EGCG Dose and Lipid Effects

The lipid effects track with EGCG dose, but the dose required to produce even modest reductions approaches the range associated with liver toxicity signals. Doses of 400-800 mg/day of EGCG in supplemental form have been studied in short-duration (8-12 week) trials with mixed LDL results and emerging safety concerns [5]. Brewed green tea, which typically delivers 50-150 mg EGCG per 8 oz cup, sits well below the hepatotoxicity threshold in clinical use.

Does Adding EGCG Improve Outcomes on Alirocumab?

No trial has studied combined alirocumab plus EGCG supplementation. Given that alirocumab can lower LDL-C by 50-60% on its own, the marginal lipid benefit of adding EGCG is almost certainly not clinically meaningful in the context of established ASCVD or familial hypercholesterolemia. The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol does not include green tea extract among recommended adjunctive therapies [6].

The Real Risk: EGCG-Induced Liver Injury

This is the part of the conversation that carries genuine clinical weight. EGCG in concentrated supplement form has a documented hepatotoxic potential that is independent of alirocumab.

Mechanism of EGCG Hepatotoxicity

EGCG at high concentrations generates reactive oxygen species in hepatocytes, impairs mitochondrial membrane potential, and can trigger apoptotic cascades [7]. The effect is dose-dependent and is substantially amplified when supplements are taken in a fasted state. A 2018 case series published in the journal Hepatology identified green tea extract as one of the most commonly implicated botanical agents in drug-induced liver injury (DILI) cases reviewed by the Drug-Induced Liver Injury Network (DILIN), accounting for approximately 9% of implicated herbal products over a 10-year observation period [8].

The 800 mg/day Threshold

The European Food Safety Authority (EFSA) concluded in a 2018 scientific opinion that EGCG intakes of 800 mg/day or more from supplements are associated with signs of liver stress, with hepatotoxicity cases reported at doses as low as 200 mg/day in susceptible individuals [9]. This threshold matters practically: many commercially available green tea extract supplements contain 400-700 mg EGCG per capsule, and consumers often take two capsules daily.

Why This Matters for Alirocumab Patients

Patients prescribed alirocumab typically have established ASCVD, familial hypercholesterolemia, or statin intolerance. The 2019 ACC Expert Consensus Decision Pathway for PCSK9 inhibitors recommends baseline and periodic liver enzyme monitoring as part of comprehensive cardiovascular risk management in this population [10]. An EGCG-induced ALT elevation could:

• Prompt unnecessary discontinuation of alirocumab if the source is not identified
• Complicate decisions about resuming or starting statin therapy
• Delay a correct DILI diagnosis if the supplement is not disclosed to the prescriber

A liver-enzyme elevation caused by undisclosed green tea extract could be misattributed to alirocumab or to residual statin exposure, introducing months of diagnostic uncertainty into an otherwise straightforward treatment plan.

CYP1A2 Inhibition by EGCG: Is It Relevant Here?

EGCG is a known inhibitor of CYP1A2 in vitro and at high doses in vivo [11]. CYP1A2 matters for drugs like clozapine, theophylline, and certain antiarrhythmics. Because alirocumab is not a CYP1A2 substrate, this inhibitory property of EGCG does not affect alirocumab clearance directly.

However, many patients on alirocumab are also prescribed statins (rosuvastatin, atorvastatin) or other cardiovascular medications. Atorvastatin is primarily metabolized by CYP3A4, which EGCG does not significantly inhibit in clinical-dose ranges. Rosuvastatin relies on OATP1B1/B3 transporters rather than CYP enzymes, so EGCG's CYP1A2 inhibition is not relevant to rosuvastatin exposure either. The most common alirocumab co-prescriptions are therefore unlikely to generate a CYP-mediated EGCG interaction [12].

P-Glycoprotein and Transporter Effects

EGCG has been shown in cell-based studies to inhibit P-glycoprotein (P-gp) and certain organic anion transporting polypeptides (OATPs) at concentrations achievable with high-dose supplements [13]. Alirocumab, as a large-molecule biologic, is not a P-gp substrate. However, patients who are also taking digoxin, certain anticoagulants, or immunosuppressants should discuss high-dose EGCG with their prescriber independently of the alirocumab question.

Practical Clinical Guidance: What to Do If You Are Already Taking Both

The following decision framework reflects HealthRX clinical editorial practice and the evidence reviewed above. It is intended as a starting scaffold for a conversation with your prescriber, not a substitute for individualized medical advice.

Step 1. Identify Your EGCG Dose

• Brewed green tea (1-4 cups/day): EGCG content roughly 50-200 mg/day total. Low hepatotoxicity concern. No action required beyond disclosure to your physician.
• Green tea extract supplement, 1 capsule/day at standard commercial dose (250-400 mg EGCG): Borderline range. Discuss with prescriber. Request baseline ALT/AST if not recently checked.
• Green tea extract supplement, 2+ capsules/day or formulations providing above 800 mg EGCG/day: High concern range per EFSA guidance. Avoid without specific clinical justification and active liver-function monitoring.

Step 2. Check for Pre-existing Liver Conditions

Patients with non-alcoholic fatty liver disease (NAFLD), prior statin-induced myopathy with elevated transaminases, or elevated baseline ALT have higher susceptibility to EGCG-related hepatotoxicity. The DILIN data suggest that genetic factors affecting oxidative stress pathways also modify individual risk [8].

Step 3. Timing and Administration

There is no pharmacokinetic rationale for separating alirocumab injections from EGCG supplement doses, given the absence of a direct PK interaction. The hepatotoxicity risk from EGCG is not injection-site or timing-dependent. Taking EGCG supplements with food consistently (rather than fasted) reduces peak hepatic EGCG exposure and is the single most actionable mitigation step for those who choose to continue [9].

Step 4. Monitoring Labs

If you continue high-dose EGCG supplementation alongside alirocumab:

• ALT and AST at baseline (before starting or at next available visit)
• Repeat at 8-12 weeks
• Discontinue EGCG and notify your physician if ALT rises above 3x the upper limit of normal

What Patients on Praluent Are Actually Asking Their Doctors

In a chart review of telehealth consultations at a preventive cardiology practice, supplement-related questions were the third most common patient-initiated inquiry during alirocumab initiation visits, after injection technique and insurance coverage. Green tea extract was the most frequently mentioned botanical supplement in that subset. Most patients were taking it for weight management rather than additional lipid lowering.

Alirocumab Efficacy Is Not Affected by EGCG

This is worth stating plainly. Even if a patient is taking high-dose EGCG simultaneously, alirocumab's ability to block PCSK9 and lower LDL-C will not be diminished. The ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab reduced major adverse cardiovascular events (MACE) by 15% versus placebo in patients with recent acute coronary syndrome (HR 0.85; 95% CI 0.78-0.93; P<0.001) [14]. That outcome benefit is biologically independent of what botanical supplements the patient is also consuming.

Special Populations: Familial Hypercholesterolemia

Patients with heterozygous familial hypercholesterolemia (HeFH) prescribed alirocumab face lifelong cardiovascular risk and are often younger, actively interested in lifestyle optimization, and more likely to be using dietary supplements. The ODYSSEY FH I and FH II trials established alirocumab 75-150 mg every two weeks as a standard-of-care option in this population, with LDL-C reductions of 49-57% at 24 weeks [15]. For HeFH patients, the goal is maximizing LDL-C reduction, and no evidence suggests EGCG makes a clinically meaningful contribution to that goal when a PCSK9 inhibitor is already achieving near-guideline LDL targets.

Comparing the Risk Profile: Brewed Tea vs. Supplement Capsules

| Source | Typical Daily EGCG | Hepatotoxicity Signal | Action | |---|---|---|---| | 1-3 cups brewed green tea | 50-150 mg | None in population studies | None required | | 1 standard GTE capsule (250-400 mg EGCG) | 250-400 mg | Low, case reports only | Disclose to prescriber | | 2+ GTE capsules or high-potency extracts | 600-1,200+ mg | EFSA concern threshold crossed | Avoid or monitor liver enzymes actively | | Matcha powder (1-2 tsp/day) | 100-200 mg | None at typical culinary doses | None required |

How to Talk to Your Prescriber

Patients often hesitate to mention supplements because they assume the physician will simply say "stop everything." A productive framing:

Bring the supplement bottle to the appointment, or photograph the supplement facts panel showing EGCG mg per serving. Ask specifically: "Is my EGCG dose in the range that would require a baseline liver-function check?" That question gives the clinician the information needed and opens a focused, efficient conversation rather than a general supplement debate.

The 2023 AHA Scientific Statement on Dietary Supplements and Cardiovascular Disease advises that "clinicians should proactively ask patients about supplement use at each encounter, using open-ended, non-judgmental language, and document specific products and doses in the medical record" [16].

Summary of Interaction Classification

Using the pharmacological framework applied in the Natural Medicines Comprehensive Database, the alirocumab-EGCG combination would be classified as:

• Pharmacokinetic interaction severity: None (no shared metabolic pathway)
• Pharmacodynamic interaction: Not clinically significant at supplemental doses
• Independent safety concern (EGCG): Moderate at doses above 400-800 mg/day
• Overall interaction classification: Monitor (conditional on EGCG dose)

This classification aligns with Mayo Clinic's general guidance that concentrated botanical supplements with known hepatotoxic potential should be disclosed to all prescribers regardless of the medications involved.

Patients taking brewed green tea, matcha, or standard-dose green tea extract (under 300 mg EGCG/day from all sources) alongside alirocumab do not require any special precaution beyond routine disclosure. Patients using high-potency GTE products should obtain a baseline ALT/AST before continuing, and the prescribing clinician should document the supplement in the medication reconciliation record.